EPS: As of FY2025 Q2, the actual value is USD 0.01.<h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and therefore has not generated any operating revenues as of June 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: For the three months ended June 30, 2025, net income was $58,716, compared to $168,692 for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended June 30, 2025, expenses were $126,616, compared to $465,800 for the same period in 2024.</li><li>Interest Earned: Interest earned on cash and investments held in the Trust Account was $185,332 for the three months ended June 30, 2025, compared to $634,492 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used was - $268,397, compared to - $518,687 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used was - $140,055, compared to $49,284,357 provided by investing activities for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided was $440,076, compared to - $49,430,380 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Trust Account Balance: As of June 30, 2025, the Trust Account balance was $22,713,372, compared to $22,206,637 as of December 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company intends to concentrate its efforts on identifying a potential Business Combination partner based in Asia (excluding China, Hong Kong, and Macau) that is developing breakthrough technology in life sciences and/or advancing a platform for sustainable technology.</li><li>Non-Core Business: The company has extended the date by which it must consummate a Business Combination multiple times, with the current extension allowing until March 3, 2026, if monthly extensions are elected.</li><li>Priority: Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, raises substantial doubt about the company’s ability to continue as a going concern.</li></ul>

VALUENCE MERGER CORP I | 10-Q: FY2025 Q2 EPS: USD 0.01